Meeting
2021 ASCO Annual Meeting
Chemoprotective effect of metformin against HR+/HER2- breast cancer among women with type-2 diabetes.
Authors
Soumya Chikermane
University of Houston, College of Pharmacy, Houston, TX
Soumya Chikermane , Susan M. Abughosh , Manvi Sharma , Meghna V. Trivedi , Rajender R. Aparasu , Michael L. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10518)
DOI
10.1200/JCO.2021.39.15_suppl.10518
Abstract #
10518
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
The role of adiposity in the association between type 2 diabetes and the risk of breast cancer.
First Author: Maria Bota
Poster
2015 ASCO Annual Meeting
Pre-diabetes and breast cancer outcomes: Abrogating the confounding effect of anti-diabetic therapy.
First Author: Varinder Kaur
Poster
2014 ASCO Annual Meeting
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).
First Author: Mira F. Liebman
Poster
2011 ASCO Annual Meeting
Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer.
First Author: A. M. Thompson